Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04342169 · ClinicalTrials.gov registry record · Phase 2
University of Utah COVID-19 Hydrochloroquine Trial
A Phase 2 study of Coronavirus and Infectious Disease, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 368
- Enrollment target
- 1
- Study location
NCT04342169 is a Phase 2 study of Coronavirus and Infectious Disease that has completed, run by University of Utah. The registered enrollment target is 368 participants, below the 1,387-participant average among 20 other Coronavirus trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04342169, a Phase 2 study of Coronavirus and Infectious Disease, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 368 participants
- Enrollment target
- 1
- Study location
Study Summary
A novel coronavirus, SARS-CoV-2, is responsible for a rapidly spreading pandemic that has reached 160 countries, infecting over 500,000 individuals and killing more than 24,000 people. SARS-CoV-2 causes an acute and potentially lethal respiratory illness, known as COVID-19, that is threatening to overwhelm health care systems due to a dramatic surge in hospitalized and critically ill patients. Patients hospitalized with COVID-19 typically have been symptomatic for 5-7 days prior to admission, indicating that there is a window during which an effective intervention could significantly alter the course of illness, lessen disease spread, and alleviate the stress on hospital resources. There is no known treatment for COVID-19, though in vitro and one poorly controlled study have identified a potential antiviral activity for HCQ. The rationale for this clinical trial is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and shedding in adult outpatients with confirmed COVID-19.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Hydroxychloroquine
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2020-04-04 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04342169
The ClinicalTrials.gov registry entry for NCT04342169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,387-participant average among 20 other Coronavirus trials with a reported enrollment target (73% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Coronavirus appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04342169 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT04342169 about?
NCT04342169 is a clinical study titled "University of Utah COVID-19 Hydrochloroquine Trial". A novel coronavirus, SARS-CoV-2, is responsible for a rapidly spreading pandemic that has reached 160 countries, infecting over 500,000 individuals and killing more than 24,000 people. SARS-CoV-2 causes an acute and potentially lethal respiratory illness, known as COVID-19, that is threatening to ov...
What is the current status of trial NCT04342169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 368 participants. The study started on 2020-04-04. Estimated completion is 2021-11-15.
What conditions does trial NCT04342169 study?
This clinical trial studies the following conditions: Coronavirus, Infectious Disease, Coronavirus Infection.
What interventions are being tested in trial NCT04342169?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04342169?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04342169 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
COMPLETED · Phase 2
-
Convalescent Plasma to Stem Coronavirus (CSSC-001)
COMPLETED · Phase 2
-
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
COMPLETED · Phase 2
-
Convalescent Plasma in the Treatment of COVID 19
COMPLETED · Phase 2
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.